XRN Stock Analysis: Chiron Real Estate | NYSE
REIT - Healthcare Facilities | NYSE, USA | Market Cap: 578m USD | 12M Return: 9.2% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 3.23M
Qual. Beats: 0
Rev. Trend: 67.8%
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.4 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Chiron Real Estate Inc. (XRN) is a net-lease medical REIT that acquires healthcare facilities and leases them to physician groups and regional and national healthcare systems. The company was established on March 18, 2011, is incorporated in Maryland, and headquartered in Bethesda, Maryland. Net-lease REITs typically structure agreements in which the tenant assumes most or all property-level operating expenses (such as taxes, insurance, and maintenance), which tends to produce predictable, long-duration cash flow for the landlord. Healthcare-focused REITs generally benefit from defensive demand characteristics, as medical services consumption is less sensitive to economic cycles than many other property types.
- Net interest expense rises as Fed rates stay elevated
- Medical facility acquisitions accelerate external AFFO growth
- Physician group reimbursement cuts pressure tenant credit quality
| Net Income: -7.67m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA 0.78 > 1.0 |
| NWC/Revenue: -429.7% < 20% (prev 22.12%; Δ -451.8% < -1%) |
| CFO/TA 0.06 > 3% & CFO 74.7m > Net Income -7.67m |
| Net Debt (681.9m) to EBITDA (89.5m): 7.62 < 3 |
| Current Ratio: 0.02 > 1.5 & < 3 |
| Outstanding Shares: last quarter (13.2m) vs 12m ago -1.04% < -2% |
| Gross Margin: 2.47% > 18% (prev 59.56%; Δ -57.09% > 0.5%) |
| Asset Turnover: 12.62% > 50% (prev 11.12%; Δ 1.50% > 0%) |
| Interest Coverage Ratio: 0.77 > 6 (EBIT TTM 29.5m / Interest Expense TTM 38.5m) |
| A: -0.55 (Total Current Assets 15.0m - Total Current Liabilities 695.1m) / Total Assets 1.24b |
| B: -0.29 (Retained Earnings -360.6m / Total Assets 1.24b) |
| C: 0.02 (EBIT TTM 29.5m / Avg Total Assets 1.25b) |
| D: 0.70 (Book Value of Equity 500.2m / Total Liabilities 717.4m) |
| Altman-Z'' = -3.66 = D |
| DSRI: 0.17 (Receivables 6.80m/36.2m, Revenue 158.3m/141.2m) |
| GMI: 24.07 (GM 59.56% / 2.47%) |
| AQI: 13.96 (AQ_t 0.98 / AQ_t-1 0.07) |
| SGI: 1.12 (Revenue 158.3m / 141.2m) |
| TATA: -0.07 (NI -7.67m - CFO 74.7m) / TA 1.24b) |
| Beneish M = 24.96 (Cap -4..+1) = D |
As of July 18, 2026, the stock is trading at USD 37.90 with a total of 64,202 shares traded. Over the past week, the price has changed by +4.35%, over one month by +8.91%, over three months by +9.17% and over the past year by +9.17%.
Current recommended Stop Loss: 36.40 (which is 4% or 1.5 ATR below the current price).
Chiron Real Estate has no consensus analysts rating.
P/E Forward = 144.9275
P/S = 3.8112
P/B = 1.398
P/EG = 5.0864
Revenue TTM = 158.3m USD
EBIT TTM = 29.5m USD
EBITDA TTM = 89.5m USD
Long Term Debt = 1.10m USD (from longTermDebt, last quarter)
Short Term Debt = 662.3m USD (from shortTermDebt, last quarter)
Debt = 690.1m USD (from shortLongTermDebtTotal, last quarter) + Leases 13.3m
Net Debt = 681.9m USD (calculated: Debt 690.1m - CCE 8.18m)
Enterprise Value = 1.26b USD (577.5m + Debt 690.1m - CCE 8.18m)
Interest Coverage Ratio = 0.77 (Ebit TTM 29.5m / Interest Expense TTM 38.5m)
EV/FCF = 49.50x (Enterprise Value 1.26b / FCF TTM 25.4m)
FCF Yield = 2.02% (FCF TTM 25.4m / Enterprise Value 1.26b)
FCF Margin = 16.08% (FCF TTM 25.4m / Revenue TTM 158.3m)
Net Margin = -4.85% (Net Income TTM -7.67m / Revenue TTM 158.3m)
Gross Margin = 2.47% ((Revenue TTM 158.3m - Cost of Revenue TTM 154.4m) / Revenue TTM)
Gross Margin QoQ = -2.21% (prev -0.09%)
Tobins Q-Ratio = 1.02 (Enterprise Value 1.26b / Total Assets 1.24b)
Interest Expense / Debt = 5.57% (Interest Expense 38.5m / Debt 690.1m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 23.3m (EBIT 29.5m * (1 - 21.00%))
Current Ratio = 0.02 (Total Current Assets 15.0m / Total Current Liabilities 695.1m)
Debt / Equity = 1.38 (Debt 690.1m / totalStockholderEquity, last quarter 500.2m)
Debt / EBITDA = 7.62 (Net Debt 681.9m / EBITDA 89.5m)
Debt / FCF = 26.80 (Net Debt 681.9m / FCF TTM 25.4m)
Total Stockholder Equity = 499.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -0.61% (Net Income -7.67m / Total Assets 1.24b)
RoE = -1.54% (Net Income TTM -7.67m / Total Stockholder Equity 499.6m)
RoCE = 5.89% (EBIT 29.5m / Capital Employed (Equity 499.6m + L.T.Debt 1.10m))
RoIC = 1.95% (NOPAT 23.3m / Invested Capital 1.20b)
WACC = 5.67% (E(577.5m)/V(1.27b) * Re(7.18%) + D(690.1m)/V(1.27b) * Rd(5.57%) * (1-Tc(0.21)))
Discount Rate = 7.18% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 86.92 | Cagr: 105.3%
[DCF] Terminal Value 77.97% ; FCFF base≈21.7m ; Y1≈24.9m ; Y5≈36.7m
[DCF] Fair Price = N/A (negative equity: EV 551.7m - Net Debt 681.9m = -130.2m; debt exceeds intrinsic value)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.73 | # QB: 0
Revenue Correlation: 67.81 | Revenue CAGR: 4.09% | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.40 | Chg30d=-344.44% | Revisions=-25% | Analysts=1
EPS next Quarter (2026-09-30): EPS=-0.37 | Chg30d=-196.00% | Revisions=-25% | Analysts=1
EPS current Year (2026-12-31): EPS=-1.50 | Chg30d=-341.18% | Revisions=-25% | GrowthEPS=+0.0% | GrowthRev=+3.7%
EPS next Year (2027-12-31): EPS=-1.53 | Chg30d=-152.89% | Revisions=-25% | GrowthEPS=-2.0% | GrowthRev=+1.1%
[Analyst] Revisions Ratio: -57% (up=0, down=4)